VR Logo

Madrigal Pharmaceuticals Inc. (MDGL) download report


Healthcare | Biotechnology & Pharma Research

Madrigal Pharmaceuticals Inc. (MDGL) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases.

IPO Date: 06-Feb-2007

Chairman & CEO: Dr. Paul A. Friedman M.D.

Founder, Chief Medical Officer, Pres of R&D and Director: Dr. Rebecca A. Taub M.D.

Listing: NASDAQ: MDGL

Country: United States

Headquarters: West Conshohocken, PA

Website: https://www.madrigalpharma.com

Key Facts

Market cap: $1,258.64 Mln

Revenue (TTM): $0.02 Mln

Earnings (TTM): $-246.82 Mln

Cash: $219.95 Mln

Total Debt: $0.70 Mln

Insider's Holding: 18.77%

Liquidity: Low

52 Week range: $52.33 - 105.93

Shares outstanding: 17,103,400

10 Years Aggregate:

  • CFO: $-730.45 Mln
  • EBITDA: $-938.41 Mln
  • Net Profit: $-926.20 Mln

Stock Performance

Time Period Madrigal Pharmaceuticals (MDGL) S&P BSE Sensex S&P Small-Cap 600
YTD-13.16-9.18-18.78
1 month7.13-4.78-8.00
3 months-25.00-9.66-13.65
1 Year-24.450.81-17.19
3 Years-11.1210.336.10
5 Years35.2511.345.87
10 Years-9.1211.749.84
As on 01-Jul-2022
Year Madrigal Pharmaceuticals (MDGL) S&P Small-Cap 600 S&P BSE Sensex
2021-23.7725.2721.99
202022.029.5715.75
2019-19.1720.8614.38
201822.66-9.705.87
2017516.0411.7327.91
201620.9424.741.95
2015-86.72-3.36-5.03